Dr. Jonasch on the Potential of Immunotherapy for Sarcomatoid RCC

Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the potential of immunotherapy for patients with sarcomatoid renal cell carcinoma (RCC).

Sarcomatoid RCC is a difficult area to treat from an efficacy standpoint, explains Jonasch. Emerging data suggest that immuno-oncology agents might be useful for this patient population.

There are published data demonstrating that PD-L1 expression is higher with sarcomatoid RCC and raises the hypothesis that targeting PD-1/PD-L1 might be beneficial, states Jonasch.